The last 17 months has certainly brought on a lot of change, some planned and some not planned. Below are some of the major topics that our U.S. life and health clients have been focused on recently – and question how best to move forward.
How Actuaries and Underwriters Can Partner to Facilitate Innovation
As part of an ongoing series in On the Risk, RGA's Taylor Pickett, an actuary, and Catie Muccigrosso, an underwriter, examine the relationship between their professions and underscore the crucial role underwriters play in the development and implementation of predictive tools and accurate pricing.
Smokeless tobacco has been evolving over the past 55 years and now, with various forms of e-cigarettes and additives available, this once ‘safer’ recreational activity is showing implications on brain, lung, and cardiovascular function.
New Medication for Alzheimer's Disease: What you need to know about Aducanumab
Aducanumab (Aduhelm), a new drug designed to treat Alzheimer's disease was approved by the FDA on June 7, 2021. RGA's Dr. Dave Rengachary discusses what this means for insurance, as well as the controversies around it.
COVID-19 Pandemic Accelerates Convergence in Insurance Distribution
How will the COVID-19 pandemic impact life and health insurance distribution and sales in the long term? Peter Rodes and Eva Goldstein of RGAX, the transformation engine of RGA, discuss the key drivers of insurance's accelerated convergence.
Monty Forman, ALHC, FALU, FLMI Director of Underwriting Research, hosts the underwriting webinar: The Thick and Thin of Melanoma. Dr. Anuj Gupta, Senior UW Research Consultant, shares his insight and the following points:
Importance in Underwriting and the clinical picture
Have you noticed that the word invasive is being bandied about more and more often in underwriting-related articles and commentaries published online and in various industry publications? This is mainly being done by those advocating radical changes in underwriting practices.
The purpose of this paper is to discuss the insurability implications of low normal/ below normal ALT in the elderly… in the hope that insurers will consider adding appropriate guidelines for this finding at older ages.